REMSleep Holdings Inc. reported significant financial challenges in its latest 10-Q filing for the first quarter of 2026, ending March 31. The company recorded no revenue during this period, maintaining the same level as the previous year. Operating expenses surged to $231,348, compared to $131,315 in the first quarter of 2025, marking an increase of approximately 76%. The net loss for the quarter was $289,924, a substantial rise from the $85,488 loss reported in the same quarter last year.
The company's balance sheet reflects a notable decline in total assets, which decreased to $223,512 from $339,756 at the end of 2025. Current assets fell significantly, primarily due to a reduction in cash reserves, which dropped to $87,953 from $214,514. Additionally, inventory levels increased to $70,356, up from $46,304, indicating potential challenges in inventory management or sales. On the liabilities side, total liabilities rose to $346,063, up from $307,694, driven by increases in accounts payable and accrued compensation.
In terms of operational developments, REMSleep Holdings did not report any new product launches or acquisitions during the quarter. However, the company did issue common stock for debt repayment, which contributed to an increase in the number of shares outstanding to 1,694,610,123, up from 1,659,190,126. The increase in employee compensation expenses, particularly related party compensation, also contributed to the higher operating costs. The company’s strategic focus appears to remain on its core mission of developing products for sleep apnea, although specific metrics on customer counts or product adoption rates were not disclosed.
The filing indicates that the company is navigating a challenging financial landscape, with increased operating expenses and a growing net loss. The management's commentary suggests that the rise in expenses is attributed to higher professional fees and general administrative costs. The company is also facing pressures from its convertible debt obligations, which have resulted in significant interest expenses. Looking ahead, REMSleep Holdings has not provided specific forward-looking statements or guidance, leaving investors to assess the company's ability to stabilize its financial performance in the coming quarters.
About RemSleep Holdings Inc.
RemSleep Holdings, Inc. develops and markets sleep apnea treatment devices, notably the patented DeltaWave nasal pillow interface designed for improved comfort and compliance. The company focuses on innovative, minimally invasive respiratory solutions, targeting sleep clinics, healthcare providers, and patients. Its business model emphasizes product development, regulatory approval, and strategic marketing within the growing sleep disorder market, competing against major industry players through proprietary technology and product differentiation.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.